Construction and the Immune Reactivity of the Anti-cancer Vaccine of recombinant Bacteriophage T7 Targeting Epidermical Growth Factor Receptor

Abstract: The overexpression of epidermical growth factor receptor (EGFR) played a vital role in the process of the formation， progression， metastasis and therapy of the malignant tumor. The monoclonal antibodys have been used for treatment of EGFR-positive expression tumors in clinical trial. In our study the N-terminal of EGFR gene was cloned from human A431 cells with RT-PCR technology and the sequence was identified. The subclone DNA fragments with different function and better presentation of mimic antigen were inserted into the bacteriophage T7 expression vector. The anti-cancer vaccine of recombinant bacteriophages T7 were constructed and the mice were immunized. The specific antibodies and the cytotoxic T lymphocyte response were detected with dot blot and MTT method， respectively. The result showed that recombinant bacteriophage T7 carrier vaccine could induced humoral immune reaction and cellular immune reaction. Therefore， the recombinant bacteriophage T7 carrier could be a kind of promising vaccine and provides a basis for the study of anti-cancer vaccine.
    
    

CSTR: 32200.14.cjcb.2006.02.0020